Scholarlink

Background <p>While genome-wide association studies (GWAS) have shown that genetic variants are linked to diabetic nephropathy (DN), the precise gene responsible for influencing risk remains largely unidentified, and the issue of missing heritability persists. This study seeks to identify new pathogenic genes using transcriptome-wide association study (TWAS) analysis in a cohort with renal biopsy-proven DN.</p> Methods <p>A TWAS was conducted to investigate potential DN risk genes whose expression mediates the genotype effect on the phenotype. Gene expression levels were entered into our existing DN GWAS cohort including 2,279 renal biopsy-proven DN and 3,762 type 2 diabetes more than 10&#xa0;years without any microvascular complications by using GEMMA software. The TWAS <i>P</i>-values were calculated using logistic regression models. Public data from ENCODE and GEO were obtained to annotate the function of genes and variants. Pathway enrichment analysis was performed with co-expressed genes. The role of <i>GYS1</i> in DN was determined using <i>Gys1</i>-antisense oligonucleotide (ASO) in db/db mice.</p> Results <p>The expression levels of 4,703 cis-heritable genes were analyzed from our renal biopsy-proven DN GWAS dataset. The TWAS results identified 17 genes (9 glomerular-only, 5 tubulointerstitial-only, and 3 shared) that were statistically significantly associated with DN susceptibility in both glomerular and tubulointerstitial regions. Notably, <i>GYS1</i> and <i>FOXJ2</i> emerged as novel findings. Furthermore, a gene prioritization strategy was developed, involving gene differential expression validation, clinical and pathological indicator correlation, and functional variant exploration. This approach identified <i>GYS1</i> as the top causal gene. Risk variants (rs116573491 and rs111518556) of <i>GYS1</i> were both discovered to increase <i>GYS1</i> expression in vitro. GYS1 was found to be enriched in glomerular mesangial cells and was elevated in DN compared to healthy controls. Additionally, the level of <i>GYS1</i> in glomeruli was inversely correlated with estimated GFR (eGFR) and positively correlated with 24-h proteinuria in DN patients. <i>Gys1</i>-ASO therapy halted the progression and development of DKD in db/db mice by reducing <i>Gys1</i> expression.</p> Conclusions <p>This biopsy-based TWAS identifies 17 DN susceptibility genes and prioritized GYS1 as a probable driver of DN, links genetic risk to mesangial dysfunction, and demonstrates that Gys1 suppression mitigates disease progression, supporting <i>GYS1</i> as a therapeutic target.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transcriptome-wide association study revealed novel causal genes of renal-biopsy proven diabetic nephropathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月11日

查看全文
  • Zijian Ma,
  • Qing Hou,
  • Ruixiang Yang,
  • Jinsong Shi,
  • Shuyan Kan,
  • Chunxia Zheng,
  • Xiaodong Zhu,
  • Zhihong Liu,
  • Song Jiang

摘要

Background

While genome-wide association studies (GWAS) have shown that genetic variants are linked to diabetic nephropathy (DN), the precise gene responsible for influencing risk remains largely unidentified, and the issue of missing heritability persists. This study seeks to identify new pathogenic genes using transcriptome-wide association study (TWAS) analysis in a cohort with renal biopsy-proven DN.

Methods

A TWAS was conducted to investigate potential DN risk genes whose expression mediates the genotype effect on the phenotype. Gene expression levels were entered into our existing DN GWAS cohort including 2,279 renal biopsy-proven DN and 3,762 type 2 diabetes more than 10 years without any microvascular complications by using GEMMA software. The TWAS P-values were calculated using logistic regression models. Public data from ENCODE and GEO were obtained to annotate the function of genes and variants. Pathway enrichment analysis was performed with co-expressed genes. The role of GYS1 in DN was determined using Gys1-antisense oligonucleotide (ASO) in db/db mice.

Results

The expression levels of 4,703 cis-heritable genes were analyzed from our renal biopsy-proven DN GWAS dataset. The TWAS results identified 17 genes (9 glomerular-only, 5 tubulointerstitial-only, and 3 shared) that were statistically significantly associated with DN susceptibility in both glomerular and tubulointerstitial regions. Notably, GYS1 and FOXJ2 emerged as novel findings. Furthermore, a gene prioritization strategy was developed, involving gene differential expression validation, clinical and pathological indicator correlation, and functional variant exploration. This approach identified GYS1 as the top causal gene. Risk variants (rs116573491 and rs111518556) of GYS1 were both discovered to increase GYS1 expression in vitro. GYS1 was found to be enriched in glomerular mesangial cells and was elevated in DN compared to healthy controls. Additionally, the level of GYS1 in glomeruli was inversely correlated with estimated GFR (eGFR) and positively correlated with 24-h proteinuria in DN patients. Gys1-ASO therapy halted the progression and development of DKD in db/db mice by reducing Gys1 expression.

Conclusions

This biopsy-based TWAS identifies 17 DN susceptibility genes and prioritized GYS1 as a probable driver of DN, links genetic risk to mesangial dysfunction, and demonstrates that Gys1 suppression mitigates disease progression, supporting GYS1 as a therapeutic target.